CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 388 enrolled
Drug / intervention
Hib-MenCY-TT vaccine +4 morebiological
Likely dose
Hib-MenCY-TT vaccine: three doses during primary vaccination and one booster dose administered intramuscularly in left thigh; or Hib-MenC-TT vaccine: three doses during primary vaccination and one booster dose administered intramuscularly in left thigh; given concomitantly with Infanrix Penta or Infanrix HexaAI-extracted
Key inclusion· 4
  • Healthy infants without major congenital illness, immunosuppression, or chronic disease
  • Born at 36 to 42 weeks of gestation
  • Between 6 and 12 weeks of age at enrollment
  • Vaccinated against hepatitis B at birth
Key exclusion· 3
  • Prior receipt of investigational drug or vaccine
  • Prior receipt of chronic immunosuppressants
  • Prior receipt of immunoglobulin or blood products

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00129116
NCT00129116Phase 2Completed

A Phase II, Open (Partially Double-blind), Randomised, Controlled, Multicentre, Primary Vaccination Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Three Different Formulations of GSK Biologicals' Combined Haemophilus Influenzae Type B-meningococcal Serogroups C and Y- Conjugate Vaccine and One Formulation of GSK Biologicals' Haemophilus Influenzae Type B-meningococcal Serogroup C Conjugate Vaccine Each Given Concomitantly With InfanrixTM Penta, Versus MeningitecTM, Given Concomitantly With InfanrixTM Hexa in Infants According to a 2-3-4 Month Schedule

GlaxoSmithKline·interventional·Posted Aug 11, 2005·Updated Aug 27, 2018

In Brief

A Phase 2 clinical trial evaluating Hib-MenCY-TT vaccine, Hib-MenC-TT vaccine, and 3 other interventions for Haemophilus Influenzae Type b and Neisseria Meningitidis. Completed, enrolled 388 participants across 26 sites in 2 countries.

Detailed Summary

This study evaluated the safety and immunogenicity of 3 formulations of Hib-MenCY-TT vaccine and 1 formulation of Hib-MenC-TT vaccine compared to a control group receiving licensed meningococcal serogroup C conjugate vaccine, each administered at 2, 3, and 4 months of age. Antibody persistence and immune responses to booster vaccinations were additionally assessed at 12 to 18 months of age.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Germany
Collaborators--

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 11, 2005
Enrollment StartMar 1, 2003
Primary CompletionDec 1, 2003
Study CompletionDec 16, 2003
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 20.9 years ago

Interventions

Hib-MenCY-TT vaccinebiological

Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.

Hib-MenC-TT vaccinebiological

Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.

Menjugate ®biological

Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.

Infanrix penta ®biological

Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.

Infanrix hexa ®biological

Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.